These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Overexpression of Mdm2 and MdmX fusion proteins alters p53 mediated transactivation, ubiquitination, and degradation. Ghosh M; Huang K; Berberich SJ Biochemistry; 2003 Mar; 42(8):2291-9. PubMed ID: 12600196 [TBL] [Abstract][Full Text] [Related]
8. An essential function of the extreme C-terminus of MDM2 can be provided by MDMX. Uldrijan S; Pannekoek WJ; Vousden KH EMBO J; 2007 Jan; 26(1):102-12. PubMed ID: 17159902 [TBL] [Abstract][Full Text] [Related]
9. Mdmx enhances p53 ubiquitination by altering the substrate preference of the Mdm2 ubiquitin ligase. Okamoto K; Taya Y; Nakagama H FEBS Lett; 2009 Sep; 583(17):2710-4. PubMed ID: 19619542 [TBL] [Abstract][Full Text] [Related]
10. Amplification of Mdmx and overexpression of MDM2 contribute to mammary carcinogenesis by substituting for p53 mutations. Yu Q; Li Y; Mu K; Li Z; Meng Q; Wu X; Wang Y; Li L Diagn Pathol; 2014 Mar; 9():71. PubMed ID: 24667108 [TBL] [Abstract][Full Text] [Related]
12. A site-directed mutagenesis study of the MdmX RING domain. Egorova O; Mis M; Sheng Y Biochem Biophys Res Commun; 2014 May; 447(4):696-701. PubMed ID: 24755078 [TBL] [Abstract][Full Text] [Related]
13. Induction of p53 expression and apoptosis by a recombinant dual-target MDM2/MDMX inhibitory protein in wild-type p53 breast cancer cells. Geng QQ; Dong DF; Chen NZ; Wu YY; Li EX; Wang J; Wang SM Int J Oncol; 2013 Dec; 43(6):1935-42. PubMed ID: 24126697 [TBL] [Abstract][Full Text] [Related]
14. Mdmx as an essential regulator of p53 activity. Marine JC; Jochemsen AG Biochem Biophys Res Commun; 2005 Jun; 331(3):750-60. PubMed ID: 15865931 [TBL] [Abstract][Full Text] [Related]
15. Mdm2 and mdmX prevent ASPP1 and ASPP2 from stimulating p53 without targeting p53 for degradation. Bergamaschi D; Samuels Y; Zhong S; Lu X Oncogene; 2005 May; 24(23):3836-41. PubMed ID: 15782125 [TBL] [Abstract][Full Text] [Related]
16. Efficient p53 activation and apoptosis by simultaneous disruption of binding to MDM2 and MDMX. Hu B; Gilkes DM; Chen J Cancer Res; 2007 Sep; 67(18):8810-7. PubMed ID: 17875722 [TBL] [Abstract][Full Text] [Related]
17. Rescue of Mdm4-deficient mice by Mdm2 reveals functional overlap of Mdm2 and Mdm4 in development. Steinman HA; Hoover KM; Keeler ML; Sands AT; Jones SN Oncogene; 2005 Nov; 24(53):7935-40. PubMed ID: 16027727 [TBL] [Abstract][Full Text] [Related]
18. MDMX: a novel p53-binding protein with some functional properties of MDM2. Shvarts A; Steegenga WT; Riteco N; van Laar T; Dekker P; Bazuine M; van Ham RC; van der Houven van Oordt W; Hateboer G; van der Eb AJ; Jochemsen AG EMBO J; 1996 Oct; 15(19):5349-57. PubMed ID: 8895579 [TBL] [Abstract][Full Text] [Related]
19. [Study of the molecular mechanisms controlling activity of protein p53 in the development of new strategies in cancer therapeutics]. Marine Ch Bull Mem Acad R Med Belg; 2009; 164(5-6):175-80; discussion 180-1. PubMed ID: 20666148 [TBL] [Abstract][Full Text] [Related]
20. MDM2 is a central node in the p53 pathway: 12 years and counting. Bond GL; Hu W; Levine AJ Curr Cancer Drug Targets; 2005 Feb; 5(1):3-8. PubMed ID: 15720184 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]